Malaria Clinical Trial
Official title:
Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana
Malaria is the most widespread parasitic illness in the world, and it is endemic to Guiana.
Although the number of cases has decreased since 2005, sources of infection still remain,
particularly within illegal gold mines. These malaria carriers/sufferers often use
self-medication to deal with malaria symptoms, resulting in a risk of resistance to
anti-malarial treatments, and particularly to artemisinine. The mobility of this population
across the Guiana Shield increases both the risk of malaria spreading and the resistance of
this illness to treatment in the region, and puts the population at risk of new outbreaks of
this disease despite the great efforts put into anti-malarial policy in this region.
Fighting malaria within this population is therefore a dual public health challenge: on the
one hand, make it possible for the WHO to eliminate malaria from the Guiana Shield by 2017,
on the other to limit resistance to artemisinine in this region. However, Guiana's
particular context - namely the illegal status of gold mines and the difficult geographical
access, the Harpie military operations, the illegality of carrying out malarial diagnosis
tests and treating cases without the presence of a health professional - prevents us from
achieving this goal using the same tools as our neighbours in Suriname, whose " Looking for
Gold, Finding Malaria " programme was a success.
A better understanding of the malarial epidemiology in this population will enable us to
propose innovative, more adapted measures to combat malaria within these guyanese
populations. This is an transversal, multicentric observational study.
Main Aim:
To estimate the prevalence of Plasmodium carriers in the population of illegal gold mine
workers in French Guiana.
Secondary aims:
Evaluate the proportion of different Plasmodium species affecting this population and
- Determine parasitaemia levels;
- Evaluate the gametocyte index;
- Map the number and proportion of P. falciparum cases for the different river sites
where gold mining is carried out;
- Determine the lifestyle, knowledge, attitude and behaviour of these populations
concerning malaria;
- Estimate the prevalence of mutations linked to the resistance of parasites to
artemisinine derivatives;
- Analyse the global genetic diversity of these parasites.
- Evaluate the global health of gold miners
The results of this study will make it possible to characterise the malaria epidemic in
illegal gold-mining sites across French Guiana, evaluate the size of the human reservoir and
the prevalence of ACT-tolerant parasites, identify the most urgent areas to be dealt with,
suggest appropriate plans of action for this, and adopt more efficient public information
campaigns.
Target Population: People working on illegal gold mining sites in French Guiana.
Inclusion Criteria:
- works on a gold mining site in French Guiana
- has been at the resting site for less than seven days
- is over the age of 18
- accepts to take part in this study
Exclusion Criteria:
- refuses to take part in the study
- is under the age of 18
The sampling of the 240 people needed for this study will be achieved through chance
meetings and the resulting snowball effect at gold mining resting sites on the Surinamese
banks of the Maroni river.
Study Protocol:
- Acquisition of authorisations from the competent French authorities
- Authorisation from the competent Surinamese authorities
- Recruitment of one mediator/translator, one state registered nurse and one doctor
- Collaboration with Dr Cairo (program "looking for gold, finding malaria) in Suriname to
plan the field missions
- Teams from Suriname and French Guiana will work joinly in the field: eligible persons
will be enrolled in the study, the others can be tested by the Surinamese team.
- Inclusion of subjects through chance meetings and the snowball effect at resting sites
- Consent of patients and checking of inclusion criteria
- Performance of three diagnostic tests for each person, including
- an RDT on site
- If the RDT is positive: complete treatment given to patient following national
guidelines;
- If necessary, provision of a results sheet describing the necessary doses for
treatment;
- Performance of thick and thin blood smears for transport to the CHAR
parasitology laboratory for analysis;
- Collection of a 5ml (EDTA) tube of blood d'un tube de sang de 5ml reserved in
an icebox between 4°C et 10°C for the CNR malarial parasitology lab at the
Institut Pasteur de la Guyane;
- Completion of the questionnaire;
- Temperature is taken;
- Patient is provided with a brochure about malaria in Portugese and/or Sranantango;
- Provision of an insecticide-treated net.
;
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |